含紫杉类方案辅助化疗对Her-2阳性乳腺癌患者生存率的影响(1)
| 第1页 |
参见附件。
【摘要】 目的 观察Her-2/neu过表达的乳腺癌患者对不同辅助化疗方案的敏感性。方法 选取2002年5月至2005年8月在我院乳腺中心接受手术且术后辅助化疗的原发性乳腺癌患者Her-2过表达者共134例,分别采用蒽环类或紫杉类方案化疗,中位随访时间38个月,分析她们的临床特征和病理学特征,不同化疗方案对无病生存期的影响。结果 Her-2过表达(++、+++)者134例,占27.7%,采用CAF方案化疗者77例,含紫杉类化疗者57例,采用CAF方案复发转移31.2%(24/77),无病生存率68.8%,含紫杉类复发率14.0%(8/57),无病生存率86%,χ2=5.290,P<0.05。结论 说明含紫杉类方案术后辅助化疗能够提高Her-2/neu过表达的乳腺癌患者的无病生存期。
【关键词】 乳腺癌;化疗;表皮生长因子-2
Study on the effects of survival rate by using adjuvant chemotherapy including paclitaxel on patients with Her-2 positive breast cancer
ZHANG Chun-zhen.Medical-department of Anyang Tumor Hospital, Anyang 455000,China
【Abstract】 Objective To investigate the effects of survival rate to paclitaxel on patients disease-free survival.Methods F rom 2002.5to 2005.8,134 cases with Her-2 positive breast cancer were followed-up until disease progress.The relationship between clinical feature,pathological type,chemotherapeutic project and survival rate were ananlyzed.Results For the patients received chemotherapy only using contained anthracycline or paclitaxel,The disease-free survival was 68 ......
您现在查看是摘要介绍页，详见PDF附件。